These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32279716)

  • 1. Treatment of Tardive Dyskinesia.
    Bashir HH; Jankovic J
    Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valbenazine for the treatment of tardive dyskinesia.
    Barquero N
    Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H; Henchcliffe C
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tardive Dyskinesia: Treatment Update.
    Arya D; Khan T; Margolius AJ; Fernandez HH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valbenazine in the treatment of tardive dyskinesia.
    Witek N; Comella C
    Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment of tardive dyskinesia.
    Margolius A; Fernandez HH
    Parkinsonism Relat Disord; 2019 Feb; 59():155-160. PubMed ID: 30591350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M; Pigato G; Kane JM; Correll CU
    Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl SM
    CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM; Nicewonder JA
    J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
    Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
    Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valbenazine for Tardive Dyskinesia.
    Freudenreich O; Remington G
    Clin Schizophr Relat Psychoses; 2017; 11(2):113-119. PubMed ID: 28742396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN; Aggarwal S; Yonan C
    J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action.
    Huang M; He W; Rajagopal L; Kudwa A; Grigoriadis DE; Meltzer HY
    Pharmacol Biochem Behav; 2020 Mar; 190():172872. PubMed ID: 32084491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.
    Davis MC; Miller BJ; Kalsi JK; Birkner T; Mathis MV
    N Engl J Med; 2017 Jun; 376(26):2503-2506. PubMed ID: 28489481
    [No Abstract]   [Full Text] [Related]  

  • 19. Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.
    Citrome LL
    J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
    Kim AP; Baker DE; Levien TL
    Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.